Partnering Opportunities

Talem Therapeutics

Talem Therapeutics is a wholly owned subsidiary of ImmunoPrecise Antibodies and is focused on the discovery and development of next-generation, fully human, monoclonal, therapeutic antibodies targeting emerging, infectious diseases, neurology, immuno-oncology, inflammation, and rare/specialty diseases. Using the proprietary antibody discovery platforms and innovative technologies housed at ImmunoPrecise Antibodies and U-Protein Express (an IPA company), Talem aims to accelerate novel, therapeutic antibody treatments to the clinic through strategic alliances and partners.

The demand for safe, therapeutic, monoclonal antibody candidates with more complex target product profiles is driving a need for more robust discoveries. Talem was founded to expedite the high-powered discovery and development of custom therapeutics produced as both internal assets as well as in response to partnership requests with large pharma.

Partner with Talem Therapeutics

We partner to discover your therapeutic antibody. By collaborating with us, we offer interested partners the use of our proprietary technologies to jointly discover and develop therapeutic antibodies against any target. We involve you in the discovery process and provide lead candidates in a short amount of time. Contact:

Leveraging our partnerships to accelerate your discovery.


AbVivo creates and licenses high-performance, mono-, bi- and poly-specific antibodies against targets with high human-rodent and intra-protein family homology and other challenges using industry-leading, avian and rodent transgenic technologies (Ligand’s OmniAb®). Partners avoid freedom-to-operate risk, species selection, animal handling and hybridoma inefficiency.

ImmunoPrecise is the exclusive partner for AbVivo in North America and Europe and accepts partners from across the globe. IPA focuses on the next generation of discovery, to deliver the most therapeutically relevant antibodies, in a shorter timeframe, with the highest probability of succeeding to the clinic. By partnering with AbVivo, we deliver antibody products discovered from Ligand OmniAb animals, which match the specific therapeutic needs of biopharmaceutical partners with flexible terms. Ligand’s unique OmniAb platform is a genetically engineered platform for the generation of diverse mono- and bispecific, fully human antibodies, and the industry’s only platform comprised of the three species rats, mice, and chickens.


Additional Information